Resnick Joshua 4

What Happened
Joshua Resnick, a member of PepGen's board of directors, received a derivative award covering 34,000 shares on June 18, 2026. The grant is reported at $0.00 per share (derivative), meaning no cash was paid by Resnick; this is a stock-based award (option/RSU-style instrument) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed four days after the reported transaction). This appears to exceed the typical two-business-day Form 4 window.
• Instrument: Derivative award covering 34,000 shares reported at $0.00 per share.
• Vesting: The award vests in full on the earlier of (i) the first anniversary of the grant or (ii) the next Annual Meeting; vesting stops if Resnick ceases to serve as a director unless the Board decides otherwise (Footnote F1).
• Beneficial ownership: Resnick holds the option for the benefit of RA Capital-managed vehicles (RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account) and disclaims beneficial ownership; any net cash or stock received upon exercise is turned over to the Adviser to offset advisory fees (Footnote F2).
• Shares owned after transaction: Not specified in the filing.

Context
This was a grant/award (not a market purchase or sale), so it does not signal a personal cash investment by the director. The filing indicates the award is held for institutional clients of RA Capital and Resnick disclaims beneficial ownership, meaning the economic benefit and voting/control implications differ from a direct personal holding.